B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus
Authors:
- 1 January 2009
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 123 (1) , e159-e163
Abstract
OBJECTIVES. Our goal was to determine long-term efficacy and safety of B-cell–depletion therapy for children with autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. PATIENTS AND METHODS. A retrospective, single-center cohort study was conducted including all patients with pediatric systemic lupus erythematosus who were diagnosed with autoimmune thrombocytopenia and/or autoimmune hemolytic anemia and treated with rituximab. Treatment efficacy and safety parameters were monitored and recorded. RESULTS. Nine patients with pediatric systemic lupus erythematosus were included in the study: 5 had autoimmune thrombocytopenia, 3 had autoimmune hemolytic anemia, and 1 had both. There were 5 female and 4 male patients; median age at diagnosis of pediatric systemic lupus erythematosus was 14 years (range: 8–16 years); and median pediatric systemic lupus erythematosus disease duration to time of rituximab treatment was 6 months (range: 2–30 months). Complete response was achieved in all 6 children with autoimmune thrombocytopenia (median time to complete response: 2 weeks [range: 1–12 weeks]). Two patients' conditions flared at 48 and 68 weeks, respectively, and were re-treated. The remaining 4 patients continued to be in remission at 24, 32, 36, and 88 weeks, respectively. All 4 children with autoimmune hemolytic anemia achieved complete response at a median time of 4 weeks (range: 4–32 weeks). All patients remained in complete response at 24, 44, 84, and 100 weeks of follow-up. Complete B-cell depletion was seen in all children after rituximab treatment. No serious infections occurred, but 1 patient had an infusion reaction. CONCLUSIONS. Preliminary evidence suggests that B-cell–depletion therapy with rituximab is an efficacious and safe treatment for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Despite the prolonged effect on B-cell numbers and function, no serious infections were observed.Keywords
This publication has 13 references indexed in Scilit:
- Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of responseAnnals of the Rheumatic Diseases, 2008
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals of the Rheumatic Diseases, 2007
- Rituximab therapy in malignant lymphomaOncogene, 2007
- Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 casesLupus, 2006
- B lymphocyte depletion therapy in children with refractory systemic lupus erythematosusArthritis & Rheumatism, 2005
- Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatmentThe Journal of Pediatrics, 2005
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosusThe Journal of Pediatrics, 2003
- Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosusRheumatology, 2003
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002